Icotrokinra meets primary endpoint in ulcerative colitis study, potentially transforming treatment for patients.
Alyftrek, a next-in-class CFTR modulator by Vertex, gains UK MHRA approval for treating cystic fibrosis in patients aged 6 and older with specific genetic mutations.
Phase III POETYK PsA-2 trial data shows Sotyktu (deucravacitinib) significantly improves outcomes in adults with psoriatic arthritis, demonstrating superiority over placebo.
Bavarian Nordic's chikungunya vaccine application accepted by UK MHRA, potentially expanding protection to individuals aged 12 and older. Approval expected in 2025.
FDA approves Revakinagene Taroretcel (LWY-ENCELTO) for treating macular telangiectasia type 2 (MacTel)
Enhertu improves overall survival in HER2-positive metastatic gastric cancer patients.
CHMP gives positive opinion for Ixchiq, a single-dose vaccine by Valneva, for preventing chikungunya virus disease.
TNX-1500 demonstrates potential in preventing organ transplant rejections and treating autoimmune diseases.
Ionis and Ono Pharma enter agreement for global rights to Sapablursen, targeting polycythemia vera.
Bristol Myers Squibb acquires 2seventy bio, including Abecma, a treatment for multiple myeloma.
